CG0070 for Bladder Cancer

Time: 1:00 pm
day: Day One

Details:

  • The data on CG0070 for NMIBC as a single agent will be reviewed
  • The data on CG0070 in combination with pembrolizumab for NMIBC will be reviewed
  • The data on CG0070 plus nivolumab for MIBC will be reviewed

Speakers: